By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
The Global Pneumatic Lithotripter Market refers to the worldwide market for medical devices specifically designed to fragment kidney stones using compressed air technology. This market exists within the broader Lithotripter market, which encompasses all technologies for treating kidney stones, including ultrasound and laser techniques.
The stone is broken using pneumatic lithotripsy, which uses a vibrating mechanical force. When compared to laser lithotripsy, it has a lower risk of ureteral perforation, but it is associated with a higher rate of stone pushing into the renal pelvis.
Specific market size or growth rate estimations might require referring to paid market research reports. Understanding the future direction of pneumatic lithotripter technology within the broader Lithotripter market would necessitate further research.
The Global Pneumatic Lithotripter Market represents a specific segment within the kidney stone treatment landscape, offering a targeted approach with compressed air technology.
The Global Pneumatic Lithotripter Market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
“NIDHILITH Digi” is a device for intracorporeal lithotripsy using direct contact pneumatic lithotripsy under endoscopic vision that is exceptionally effective, safe, and reliable. It’s a microprocessor-based digitally controlled pressure flow device that provides high-accurate pluses in single pulse and variable continuous pulse modes for stone fragmentation in the urinary system, including the kidney, ureter, and bladder.
The stiff probe design is one of the most noticeable and distinguishing features of “NIDHILITH Digi.” This causes huge and hard calculi to be fragmented quickly and safely anywhere in the urinary system, including the kidneys, ureters, and bladder. As a result, there is no risk of heat development at the probe’s tip and subsequent mucosal injury.
Dornier MedTech America, a multinational medical device firm and the inventor of Extracorporeal Shock Wave Lithotripsy, has been granted FDA approval to market the Delta III. The Delta II, the world’s best-selling and most clinically cited lithotripter, has been updated. Dornier’s continuous dedication to creating cutting-edge kidney stone treatment options is shown in the Delta III.
The Delta III outperforms its predecessor in terms of Powerful Imaging, Maximised Energy, and Efficiency.
By Technology:
By Stone Characteristics:
By Application:
By Geographic Region: